Zydus files IND application for dyslipidemia compound
This article was originally published in Scrip
Executive Summary
Zydus Cadilahas filed an IND for a lipid lowering molecule with the Drugs Controller General of India. The company claims that the new compound, ZYT1, may provide an alternative to statins or be an add-on to statin therapy. In preclinical studies, ZYT1 has shown a beneficial effect on LDL-cholesterol and triglycerides, compared with the effects seen with statins. When combined with statins, ZYT1 has shown a "pronounced effect" in lowering LDL-cholesterol and triglycerides and has a very high margin of safety, Zydus said. The company now has six compounds in various stages of clinical development, with two candidates in advanced Phase II. The company's R&D is focused on the metabolic, cardiovascular and inflammation segments.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.